
    
      Following the 4-week Screening Period, eligible subjects will be randomized to enter the 12
      weeks placebo-controlled Induction Period (IP). Subjects who are responders at Week 12 will
      continue on their assigned treatment in the 52-week Maintenance Period (MP). Non responders
      at Week 12 have the option to enter the Open-label Extension (OLE). Subjects who complete the
      MP will be given the option to participate in the OLE. Subjects that enter the MP and
      experience disease relapse will also have the option to enter the OLE. The OLE will continue
      until marketing launch (about 4 years of ozanimod for Ulcerative colitis (UC), or until the
      Sponsor discontinues the development program.
    
  